Summary
EudraCT Number: 2006-000977-31
Sponsor's Protocol Code Number: NV25361
National Competent Authority: Italy - Italian Medicines Agency 
Clinical Trial Type: EEA CTA
Trial Status: Completed
Date on which this record was first entered in the EudraCT database: 2021-05-24
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000977-31/IT/

A. Protocol Information
A.1 Member State Concerned: Italy - Italian Medicines Agency
A.2 EudraCT number: 2006-000977-31
A.3 Full title of the trial: PHASE IIIB, RANDOMIZED, OPEN LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE OR
ENTECAVIR COMPARED WITH UNTREATED CONTROL PATIENTS IN CHILDREN WITH HBEAG POSITIVE CHRONIC HEPATITIS B IN THE IMMUNE
TOLERANT PHASE
A.3 Full title of the trial (it): STUDIO DI FASE IIIB, RANDOMIZZATO, IN APERTO, CON INTERFERONE PEGILATO ALFA-2A IN ASSOCIAZIONE A LAMIVUDINA O ENTECAVIR,
RISPETTO AL CONTROLLO DI PAZIENTI SENZA
TRATTAMENTO, IN BAMBINI AFFETTI DA EPATITE B CRONICA HBEAG-POSITIVA IN FASE
IMMUNOTOLLERANTE
A.3.1 Title of the trial for lay people, in easily understood, i.e. non-technical, language: A Study of Pegasys in Combination with antiviral HBV oral Lamivudine or entecavir compared against no treatment in Children Positive but
tolerant to Chronic Hepatitis B.
A.3.1 Title of the trial for lay people, in easily understood, i.e. non-technical, language (it): STUDIO CON INTERFERONE PEGILATO ALFA-2A O ENTECAVIR IN ASSOCIAZIONE
A LAMIVUDINA
A.3.2 Name or abbreviated title of the trial where available: STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE
A.3.2 Name or abbreviated title of the trial where available (it): STUDIO CON INTERFERONE PEGILATO ALFA-2A IN ASSOCIAZIONE A LAMIVUDINA
A.4.1 Sponsor's protocol code number: NV25361
A.7 Trial is part of a Paediatric Investigation Plan: Yes
A.8 EMA Decision number of Paediatric Investigation Plan: P/010/2016

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: F. HOFFMANN - LA ROCHE LTD.
B.1.3.4	Country: Switzerland
B.3.1 and B.3.2	Status of the sponsor: Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support: F. Hoffmann La Roche Ltd.
B.4.2 Country: Switzerland
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: F. Hoffmann-La Roche Ltd
B.5.2 Functional name of contact point: Trial Information Support Line-TISL
B.5.3 Address
B.5.3.1 Street Address: Grenzacherstrasse 124
B.5.3.2 Town/ city: Basel
B.5.3.3 Post code: 4070
B.5.3.4 Country: Switzerland
B.5.4 Telephone number: 0
B.5.5 Fax number: 0
B.5.6 E-mail: global.rochegenentechtrials@roche.com

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: Pegasys
D.2.1.1.2 Name of the Marketing Authorisation holder: Roche Registration Ltd
D.2.1.2 Country which granted the Marketing Authorisation: United Kingdom
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Pegasys
D.3.2 Product code: RO025-8310
D.3.4 Pharmaceutical form: Solution for injection
D.3.4.1 Specific paediatric formulation: Yes
D.3.7 Routes of administration for this IMP:
Subcutaneous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: INTERFERONE ALFA-2A PEGILATO
D.3.9.1 CAS number: 76543-88-9
D.3.9.2 Current sponsor code: Ro025-8310/J13
D.3.9.3 Other descriptive name: Interferon alfa-2a
D.3.10 Strength
D.3.10.1 Concentration unit: µg/ml microgram(s)/millilitre
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 180 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: No
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Yes
D.3.11.3 Advanced Therapy IMP (ATIMP): No
D.3.11.3.1 Somatic cell therapy medicinal product: Information not present in EudraCT
D.3.11.3.2 Gene therapy medical product: Information not present in EudraCT
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: No
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Yes
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: Yes
D.3.11.13.1 Other medicinal product type: Immunostimulating agent/cytokine
D.IMP: 2
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: Epivir
D.2.1.1.2 Name of the Marketing Authorisation holder: ViiV Healthcare UK Ltd.
D.2.1.2 Country which granted the Marketing Authorisation: United Kingdom
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Oral solution
D.3.4.1 Specific paediatric formulation: No
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: LAMIVUDINA
D.3.9.1 CAS number: 134678-17-4
D.3.9.2 Current sponsor code: -
D.3.9.3 Other descriptive name: LAMIVUDINE
D.3.9.4 EV Substance Code: SUB08392MIG
D.3.10 Strength
D.3.10.1 Concentration unit: mg/ml milligram(s)/millilitre
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 10 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): No
D.3.11.3.1 Somatic cell therapy medicinal product: Information not present in EudraCT
D.3.11.3.2 Gene therapy medical product: Information not present in EudraCT
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: No
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: No
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 3
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: Lamivudine
D.2.1.1.2 Name of the Marketing Authorisation holder: TEVA Pharma B.V
D.2.1.2 Country which granted the Marketing Authorisation: United Kingdom
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Film-coated tablet
D.3.4.1 Specific paediatric formulation: No
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: LAMIVUDINA
D.3.9.1 CAS number: 134678-17-4
D.3.9.2 Current sponsor code: -
D.3.9.3 Other descriptive name: LAMIVUDINE
D.3.9.4 EV Substance Code: SUB08392MIG
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 100 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): No
D.3.11.3.1 Somatic cell therapy medicinal product: Information not present in EudraCT
D.3.11.3.2 Gene therapy medical product: Information not present in EudraCT
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: No
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: No
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No

D.8 Information on Placebo

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: Chronic Hepatitis B Virus infection in children.
E.1.1 Medical condition(s) being investigated (it): infezione da virus dell'epatite C cronica in bambini
E.1.1.1 Medical condition in easily understood language: Chronic Hepatitis B in immune-tolerant phase with high levels of hepatitis B virus in the blood and low (if any) liver damage
E.1.1.1 Medical condition in easily understood language (it): Epatite B cronica in fase immuno-tollerante con alti livelli di virus dell'epatite B nel sangue e (se del caso) con danno non grave al fegato
E.1.1.2 Therapeutic area: Diseases [C] - Virus Diseases [C02]
MedDRA Classification
E.1.2 Medical condition or disease under investigation:
E.1.2 Version: 20.0
E.1.2 Level: LLT
E.1.2 Classification code: 10019743
E.1.2 Term: Hepatitis B virus (HBV)
E.1.2 System Organ Class: 100000004848
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: To evaluate the efficacy of Pegasys¿ + lamivudine compared with an untreated control in children with CHB, as measured by loss of HBsAg 24 weeks post-end of treatment/end of untreated observation.
E.2.1 Main objective of the trial (it): Valutare l'efficacia di Pegasys¿ + lamivudina rispetto a un controllo senza trattamento in bambini affetti da epatite B cronica (CHB), misurandola in termini di perdita di HBsAg 24 settimane dopo la fine del trattamento/fine dell'osservazione senza trattamento.
E.2.2 Secondary objectives of the trial: ¿To evaluate efficacy of Pegasys¿ + lamivudine compared with an untreated control in children with CHB, as measured by seroconversion to anti-HBs, seroconversion to anti-HBe, loss of HBeAg, and HBV DNA levels, at 24 weeks post-end of treatment/end of untreated observation 
¿ To evaluate efficacy of Pegasys¿ + lamivudine in children with CHB, as measured by seroconversion to anti-HBs, seroconversion to anti-HBe, loss of HBsAg, loss of HBeAg, HBV DNA levels, and at 1, 2, 3, 4, and 5 years post-end of treatment 
E.2.2 Secondary objectives of the trial (it): -Valutare l'efficacia di Pegasys¿ + lamivudina rispetto a un controllo senza trattamento in bambini affetti da epatite B cronica (CHB), misurandola in termini di sieroconversione ad anti-HBs, sieroconversione ad anti-HBe, perdita di HBeAg e dei livelli di HBV DNA 24 settimane dopo la fine del trattamento/fine dell'osservazione senza trattamento.
- Valutare l'efficacia di Pegasys¿ + lamivudina in bambini affetti da epatite B cronica (CHB), misurandola in termini di sieroconversione ad anti-HBs, sieroconversione ad anti-HBe, perdita di HBsAg, perdita di HBeAg, e dei livelli di HBV DNA a 1, 2, 3, 4 e 5 anni dopo la fine del trattamento.
E.2.3 Trial contains a sub-study: No
E.3 Principal inclusion criteria: • Male and female patients 3 to less than 18 years of age at baseline (12– 17 years of age at baseline in Russia)
• Positive for HBsAg and HBeAg for more than 6 months prior to baseline
• Detectable HBV-DNA (> 10,000 copies/mL [> 2000 IU/mL]) (as measured by PCR or hybridization) on at least 2 occasions at least one month apart with the latest determination obtained = 42 days prior to
baseline.
E.3 Principal inclusion criteria (it): - Pazienti di entrambi i sessi, di età inferiore ai 18 anni al basale (o tra 12 e 17 anni di età al basale in Russia).
- Positivi per HBsAg e HBeAg per oltre 6 mesi prima del basale.
- HBV DNA rilevabile (> 10.000 copie/ml [> 2000 UI/ml]) (valore misurato mediante reazione a catena della polimerasi [PCR] o ibridazione) in almeno 2 occasioni distanziate di almeno un mese, con l'ultima determinazione ottenuta = 42 giorni prima del basale.
E.4 Principal exclusion criteria: Patients who have had any previous anti-HBV treatment, or who are co-infected with hepatitis A virus (HAV), HCV, hepatitis D virus (HDV) or HIV, or who have decompensated liver disease will be excluded.
E.4 Principal exclusion criteria (it): Vengono esclusi pazienti trattati con altri trattamenti anti-HBV o co-infettati dal virus dell'epatite A (HAV), HCV, virus dell'epatite D (HDV), HIV, o che hanno epatopatia non compensata
E.5 End points
E.5.1 Primary end point(s): The primary efficacy endpoint is defined as loss of HBsAg at 24 weeks post-end of treatment (follow-up Week 24)/end of untreated observation (Week 80).
E.5.1 Primary end point(s) (it): L'endpoint primario di efficacia è la perdita di HBsAg a 24 settimane dopo la fine del trattamento (follow-up Week 24) /fine dell'osservazione senza trattamento (Week 80).
E.5.1.1 Timepoint(s) of evaluation of this end point: Please refer to E.5.1
E.5.1.1 Timepoint(s) of evaluation of this end point (it): Vedere sezione E.5.1
E.5.2 Secondary end point(s): - Seroconversion to anti-HBs (loss of HBsAg and presence of anti-HBs)
- Seroconversion to anti-HBe (loss of HBeAg and presence of anti-HBe)
- Loss of HBeAg
- HBV DNA DNA < 100,000 copies/mL (< 20,000 IU/mL), < 10,000
copies/mL (< 2000 IU/mL) , undetectable and change from baseline (by PCR or hybridization)
- Combined endpoints: HBeAg seroconversion and HBV DNA < 100,000 copies/mL (< 20,000 IU/mL)
- Combined endpoints: HBeAg seroconversion and HBV DNA < 10,000 copies/mL (< 2000 IU/mL); - Seroconversion to anti-HBs (loss of HBsAg and presence of anti-HBs)
- Seroconversion to anti-HBe (loss of HBeAg and presence of anti-HBe)
- Loss of HBsAg
- Loss of HBeAg
- HBV DNA < 100,000 copies/mL (< 20,000 IU/mL), < 10,000 copies/mL (< 2000 IU/mL), undetectable and change from baseline (by PCR or hybridization)
- Combined endpoints: HBeAg seroconversion and HBV DNA < 100,000 copies/mL (< 20,000 IU/mL)
- Combined endpoints: HBeAg seroconversion and HBV DNA < 10,000 copies/mL (< 2000 IU/mL)
E.5.2 Secondary end point(s) (it): - Perdita di HBeAg
¿ Sieroconversione ad anti-HBs (perdita di HBsAg e presenza di anti-HBs)
¿ Sieroconversione ad anti-HBe (perdita di HBeAg e presenza di anti-HBe)
¿ HBV DNA < 100,000 copie/ml (< 20.000 UI/ml), < 10,000 copie/ml (< 2000 UI/ml), irrilevabile e variazione rispetto al basale (mediante PCR o ibridazione)
¿ Endpoint combinati: sieroconversione di HBeAg e HBV DNA < 100,000 copie/ml (< 20.000 UI/ml)
¿ Endpoint combinati: sieroconversione di HBeAg e HBV DNA < 10,000 copie/ml (< 2.000 UI/ml).; - Perdita di HBsAg
- Perdita di HBeAg
- Sieroconversione ad anti-HBs (perdita di HBsAg e presenza di anti-HBs)
- Sieroconversione ad anti-HBe (perdita di HBeAg e presenza di anti-HBe)
- HBV DNA < 100,000 copie/ml (< 20.000 UI/ml), < 10,000 copie/ml (< 2000 UI/ml), irrilevabile e variazione rispetto al basale (mediante PCR o ibridazione)
- Endpoint combinati: sieroconversione di HBeAg e HBV DNA < 100,000 copie/ml (< 20.000 UI/ml)
¿ Endpoint combinati: sieroconversione di HBeAg e HBV DNA < 10,000 copie/ml (< 2.000 UI/ml).
E.5.2.1 Timepoint(s) of evaluation of this end point: Please refer to E.5.2; Please refer to E.5.2
E.5.2.1 Timepoint(s) of evaluation of this end point (it): Fare riferimento alla sezione E 5.2; Fare riferimento alla sezione E 5.2
E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: No
E.6.2 Prophylaxis: No
E.6.3 Therapy: Yes
E.6.4 Safety: Yes
E.6.5 Efficacy: Yes
E.6.6 Pharmacokinetic: Yes
E.6.7 Pharmacodynamic: Yes
E.6.8 Bioequivalence: No
E.6.9 Dose response: No
E.6.10 Pharmacogenetic: No
E.6.11 Pharmacogenomic: No
E.6.12 Pharmacoeconomic: No
E.6.13 Others: No
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: No
E.7.1.2 Bioequivalence study: No
E.7.1.3 Other: No
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): No
E.7.3 Therapeutic confirmatory (Phase III): Yes
E.7.4 Therapeutic use (Phase IV): No
E.8 Design of the trial
E.8.1 Controlled: Yes
E.8.1.1 Randomised: Yes
E.8.1.2 Open: Yes
E.8.1.3 Single blind: No
E.8.1.4 Double blind: No
E.8.1.5 Parallel group: Yes
E.8.1.6 Cross over: No
E.8.1.7 Other: No
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): No
E.8.2.2 Placebo: No
E.8.2.3 Other: Yes
E.8.2.3.1 Comparator description: No treatment
E.8.2.3.1 Comparator description (it): Nessun trattamento
E.8.2.4 Number of treatment arms in the trial: 2
E.8.3 The trial involves single site in the Member State concerned: No
E.8.4 The trial involves multiple sites in the Member State concerned: Yes
E.8.4.1 Number of sites anticipated in Member State concerned: 2
E.8.5 The trial involves multiple Member States: Yes
E.8.5.1 Number of sites anticipated in the EEA: 15
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: Yes
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.6.3 If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned:
China
Russian Federation
Taiwan
Turkey
Ukraine
Germany
Italy
Romania
United Kingdom
E.8.7 Trial has a data monitoring committee: Yes
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: LVLS (the end of the study is defined as the date when the last patient, last visit for the final analysis occurs)
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial (it): LVLS (per fine dello studio si intende la data in cui ha luogo l'ultima visita dell'ultimo paziente per l'analisi finale).
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 7
E.8.9.1 In the Member State concerned months: 0
E.8.9.1 In the Member State concerned days: 0
E.8.9.2 In all countries concerned by the trial years: 16
E.8.9.2 In all countries concerned by the trial months: 6
E.8.9.2 In all countries concerned by the trial days: 0

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: Yes
F.1.1.1 In Utero: No
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): No
F.1.1.3 Newborns (0-27 days): No
F.1.1.4 Infants and toddlers (28 days-23 months): No
F.1.1.5 Children (2-11years): Yes
F.1.1.5.1 Number of subjects for this age range: 57
F.1.1.6 Adolescents (12-17 years): Yes
F.1.1.6.1 Number of subjects for this age range: 57
F.1.2 Adults (18-64 years): No
F.1.3 Elderly (>=65 years): No
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: Yes
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: Yes
F.3.3.1 Women of childbearing potential not using contraception : No
F.3.3.2 Women of child-bearing potential using contraception: Yes
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: Yes
F.3.3.6.1 Details of subjects incapable of giving consent: Children from ages 3 to 17
F.3.3.6.1 Details of subjects incapable of giving consent (it): Bambini dai 3 ai 17 anni 
F.3.3.7 Others: No
F.4 Planned number of subjects to be included
F.4.1 In the member state: 4
F.4.2 For a multinational trial
F.4.2.1 In the EEA: 57
F.4.2.2 In the whole clinical trial: 114
F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition): All treated patients will be followed for 5 years after the end of treatment (24 weeks initial follow-up plus a further 4.5-year long-term follow-up) for evaluation of any longer-term effects of treatment.
F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition) (it): Tutti i pazienti trattati verranno seguiti per 5 anni dopo la fine del trattmento (24 settimane di follow-up iniziale e altri 4,5 anni di follow-up a lungo termine) per la valutazione degli effetti del trattamento a lungo termine

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2015-08-10
N. Ethics Committee Opinion of the trial application: 
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 

P. End of Trial
P. End of Trial Status: Completed

